RCE

What RCE does

RCE Technologies, Inc. is a pre-commercial medical technology company developing the Infrasensor, a wrist-worn wearable device that uses proprietary mid-infrared (MIR) spectroscopy combined with deep learning to detect early stages of severe coronary artery occlusion non-invasively. The device captures transdermal derived infrared spectrophotometric (TDIS) waveforms through the skin, processes them via proprietary ML algorithms, and delivers a cardiac assessment in approximately three minutes without the need for an invasive blood draw. RCE is pursuing FDA de novo pre-market clearance, with a pivotal study in Emergency Departments initiated in 2025 and FDA presubmission already completed.

The company's core technology rests on four issued US patents covering infrared sensor architecture, cardiac monitoring methods, and the wearable form factor, supported by a proprietary clinical dataset of 840+ patients enrolled across 10 US hospital sites. RCE's clinical evidence has been validated through publication in Nature Communications Medicine and the European Heart Journal, and through presentations at the American College of Cardiology Late Breaking Clinical Trials. The company's Scientific Advisory Board includes KOL cardiologists from leading academic centers (Baylor College of Medicine, Rutgers Robert Wood Johnson, and others), and its leadership includes a Chief Medical Officer with prior service as Senior Medical Officer at the FDA's Digital Health Center of Excellence.

RCE's go-to-market is sales-led and clinically validated, initially targeting Emergency Departments, urgent care facilities, and EMS/ambulance services, with secondary use cases in pharmaceutical cardiovascular drug trials and at-home monitoring of high-risk CAD patients. The company has secured a first commercial Letter of Intent, but remains pre-revenue. Future expansion includes the Infrasensor-home consumer wearable and licensing its AI sensor technology for integration into existing patch and watch-based platforms. The company is headquartered in Carlsbad, California, was founded in 2018, and has completed accelerator programs at TMCx and Cedars-Sinai.

Name

RCE

Legal name

RCE Technologies, Inc.

Website

https://rce.ai

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

RCE Technologies is a pre-commercial med-tech company developing the Infrasensor, a wrist-worn wearable that uses proprietary mid-infrared spectroscopy and machine learning to detect early stages of severe heart attacks non-invasively, targeting hospital emergency departments, urgent care, and EMS.

Ownership category

akta.pro rank

Product category

Cardiac Diagnostic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

akta.pro secondary industries

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Cardiology Telemedicine Platforms (HLALAGAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

Keywords

• Cardiac biomarker detection
• Infrared spectroscopy wearables
• Heart attack diagnostics
• Non-invasive cardiac monitoring
• Medical infrared sensors

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Wearable Device Sales: Pre-commercial stage. Revenue expected from sale of wrist-worn wearable devices with integrated infrared sensors for cardiac monitoring.

Go-to-market motion3 records

Marketing channels5 records

Core offering

RCE Technologies develops and is commercializing the Infrasensor, a wrist-worn wearable medical device that combines proprietary mid-infrared spectroscopy sensors with cloud-based machine learning to non-invasively measure cardiac biomarkers transdermally and detect early stages of severe coronary artery occlusion (high-grade obstructive NSTE-ACS) in approximately three minutes. The investigational device is targeted at hospital emergency departments, urgent care centers, EMS providers, pharmaceutical trial sponsors, and high-risk at-home CAD patients, with FDA de novo pre-market clearance currently in process.

Differentiator

Problem solved

Functional benefit

Brands

• Infrasensor: A non-invasive wrist-worn device for detection of high-grade obstructive Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) using infrared spectroscopy technology.

Products and services

• Infrasensor A wrist-worn wearable medical device that uses proprietary mid-infrared spectroscopy sensors and cloud-based machine learning to non-invasively analyze Transdermal Derived Infrared Spectrophotometric (TDIS) waveforms from the skin and detect early stages of severe coronary artery occlusion (high-grade obstructive NSTE-ACS) in approximately three minutes. Currently an investigational device used for research only, pending FDA de novo pre-market clearance; intended for hospital emergency departments, urgent care centers, EMS providers, and pharmaceutical trial sponsors.

Quantifiable outcome

• 3-minute non-invasive cardiac assessment
• +1 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• American Heart AssociationflagshipStrategic or Co-development PartnerAmerican Heart Association is a key strategic partner and has recognized RCE as a Health Tech Winner. The partnership provides credibility in the cardiovascular health space and access to AHA's network and resources.
• Cedars-Sinai AcceleratorcoreStrategic or Co-development PartnerRCE participated in the Cedars-Sinai Accelerator program, gaining access to clinical expertise, hospital network validation opportunities, and mentorship from healthcare industry veterans.
• Texas Medical Center (TMCx)coreStrategic or Co-development PartnerRCE completed the TMCx accelerator program, providing access to the world's largest medical complex for clinical validation and healthcare system partnerships.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AliveCor: AliveCor makes KardiaMobile, a clinical-grade single-lead ECG device for at-home and point-of-care cardiac rhythm assessment. It is the closest direct peer because it sells a consumer/clinical hardware device using AI/ML to detect cardiac abnormalities (arrhythmias) outside the hospital, overlapping with RCE's wrist-worn AI cardiac biomarker platform in use case and customer profile.
• iRhythm Technologies: iRhythm's Zio long-term ambulatory ECG patch and AI-based arrhythmia detection platform is a direct clinical cardiology diagnostic competitor. It shares RCE's profile of an AI-enabled wearable cardiac diagnostic with FDA clearance, hospital channel sales, and reimbursement-driven economics.
• Eko Health: Eko combines digital stethoscopes with FDA-cleared AI algorithms (including for cardiac biomarkers and murmurs) for clinicians in primary care and ED settings. It competes on the same problem RCE solves, using a different sensor modality, and shares a hospital sales motion plus AI/ML device regulatory playbook.
• HeartFlow: HeartFlow provides AI-driven non-invasive cardiac diagnostics (CT-derived FFR) for coronary artery disease assessment. It is comparable as an AI-first, non-invasive alternative to invasive cardiac diagnostics sold into the same cardiology customer base as RCE.

Broad incumbents

• Abbott Diagnostics: Abbott's ARCHITECT and Alinity high-sensitivity troponin assays plus its i-STAT point-of-care troponin platform dominate the ED cardiac biomarker market that RCE would enter. Comparable as the incumbent whose installed base, turnaround improvements, and hospital contracts RCE must displace or complement.
• Roche Diagnostics: Roche's Elecsys high-sensitivity troponin-T assays are the global standard for ED cardiac biomarker testing. Relevant as the entrenched competitor with deep hospital integration, continuous assay improvements, and clinical guideline endorsements that RCE must compete against.
• Siemens Healthineers: Siemens Healthineers markets Atellica and ADVIA Centaur high-sensitivity troponin-I assays and a broad hospital diagnostics portfolio. It is comparable as an incumbent cardiac biomarker vendor whose assay iteration cadence sets the competitive bar for RCE's launch.
• GE HealthCare: GE HealthCare's MUSE ECG management, inpatient telemetry/monitoring, and patient monitoring portfolio competes in the same hospital cardiology workflow RCE targets. Relevant as a broad incumbent with established hospital relationships and integrated cardiology IT platforms.
• Philips (Cardiac Monitoring): Philips sells cardiac telemetry, ECG, and acute care monitoring solutions into hospital systems globally. Comparable as a broad incumbent selling into the same cardiology and ED/ICU buyer, with established integration, training, and service infrastructure that RCE would need to match.

Emerging players

• Cleerly Health: Cleerly applies AI to cardiac CT imaging for plaque and stenosis assessment in coronary artery disease. It overlaps with RCE as an emerging AI-driven, non-invasive cardiology diagnostic targeting similar hospital and cardiology customers, though with an imaging rather than wearable sensor modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/rce_ai
• LinkedInlinkedin.com/company/rcetechnologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RCE